These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 33237382)

  • 41. A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions.
    Guo H; Liu C; Li J; Zhang M; Hu M; Xu P; Liu L; Liu X
    J Pharm Sci; 2013 Aug; 102(8):2819-36. PubMed ID: 23760985
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expanded Physiologically-Based Pharmacokinetic Model of Rifampicin for Predicting Interactions With Drugs and an Endogenous Biomarker via Complex Mechanisms Including Organic Anion Transporting Polypeptide 1B Induction.
    Asaumi R; Menzel K; Lee W; Nunoya KI; Imawaka H; Kusuhara H; Sugiyama Y
    CPT Pharmacometrics Syst Pharmacol; 2019 Nov; 8(11):845-857. PubMed ID: 31420941
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions.
    Ono C; Hsyu PH; Abbas R; Loi CM; Yamazaki S
    Drug Metab Dispos; 2017 Apr; 45(4):390-398. PubMed ID: 28167538
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Physiologically Based Pharmacokinetic Modelling of Cabozantinib to Simulate Enterohepatic Recirculation, Drug-Drug Interaction with Rifampin and Liver Impairment.
    Gerner B; Scherf-Clavel O
    Pharmaceutics; 2021 May; 13(6):. PubMed ID: 34067429
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of cynomolgus monkeys for the identification of endogenous biomarkers for hepatic transporter inhibition and as a translatable model to predict pharmacokinetic interactions with statins in humans.
    Chu X; Shih SJ; Shaw R; Hentze H; Chan GH; Owens K; Wang S; Cai X; Newton D; Castro-Perez J; Salituro G; Palamanda J; Fernandis A; Ng CK; Liaw A; Savage MJ; Evers R
    Drug Metab Dispos; 2015 Jun; 43(6):851-63. PubMed ID: 25813937
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin.
    Mamidi RNVS; Dallas S; Sensenhauser C; Lim HK; Scheers E; Verboven P; Cuyckens F; Leclercq L; Evans DC; Kelley MF; Johnson MD; Snoeys J
    Br J Clin Pharmacol; 2017 May; 83(5):1082-1096. PubMed ID: 27862160
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predicting the effect of cytochrome P450 inhibitors on substrate drugs: analysis of physiologically based pharmacokinetic modeling submissions to the US Food and Drug Administration.
    Wagner C; Pan Y; Hsu V; Grillo JA; Zhang L; Reynolds KS; Sinha V; Zhao P
    Clin Pharmacokinet; 2015 Jan; 54(1):117-27. PubMed ID: 25260695
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A generic framework for the physiologically-based pharmacokinetic platform qualification of PK-Sim and its application to predicting cytochrome P450 3A4-mediated drug-drug interactions.
    Frechen S; Solodenko J; Wendl T; Dallmann A; Ince I; Lehr T; Lippert J; Burghaus R
    CPT Pharmacometrics Syst Pharmacol; 2021 Jun; 10(6):633-644. PubMed ID: 33946131
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Contribution of Uptake and Efflux Transporters to Oral Pharmacokinetics of Furosemide.
    Chapa R; Li CY; Basit A; Thakur A; Ladumor MK; Sharma S; Singh S; Selen A; Prasad B
    ACS Omega; 2020 Dec; 5(51):32939-32950. PubMed ID: 33403255
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Physiologically-Based Pharmacokinetic Model of Trimethoprim for MATE1, OCT1, OCT2, and CYP2C8 Drug-Drug-Gene Interaction Predictions.
    Türk D; Hanke N; Lehr T
    Pharmaceutics; 2020 Nov; 12(11):. PubMed ID: 33182761
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Quantitative prediction of renal transporter-mediated clinical drug-drug interactions.
    Feng B; Hurst S; Lu Y; Varma MV; Rotter CJ; El-Kattan A; Lockwood P; Corrigan B
    Mol Pharm; 2013 Nov; 10(11):4207-15. PubMed ID: 24066726
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quantitative Analyses of the Influence of Parameters Governing Rate-Determining Process of Hepatic Elimination of Drugs on the Magnitudes of Drug-Drug Interactions via Hepatic OATPs and CYP3A Using Physiologically Based Pharmacokinetic Models.
    Yoshikado T; Maeda K; Kusuhara H; Furihata KI; Sugiyama Y
    J Pharm Sci; 2017 Sep; 106(9):2739-2750. PubMed ID: 28495568
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects.
    Cimoch PJ; Lavelle J; Pollard R; Griffy KG; Wong R; Tarnowski TL; Casserella S; Jung D
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Mar; 17(3):227-34. PubMed ID: 9495222
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of Mrp2 on the biliary excretion and intestinal absorption of furosemide, probenecid, and methotrexate using Eisai hyperbilirubinemic rats.
    Chen C; Scott D; Hanson E; Franco J; Berryman E; Volberg M; Liu X
    Pharm Res; 2003 Jan; 20(1):31-7. PubMed ID: 12608533
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactions.
    Lang J; Vincent L; Chenel M; Ogungbenro K; Galetin A
    Eur J Pharm Sci; 2021 Oct; 165():105932. PubMed ID: 34260894
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling.
    Rajoli RKR; Curley P; Chiong J; Back D; Flexner C; Owen A; Siccardi M
    J Infect Dis; 2019 May; 219(11):1735-1742. PubMed ID: 30566691
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Optimization of a drug transporter probe cocktail: potential screening tool for transporter-mediated drug-drug interactions.
    Stopfer P; Giessmann T; Hohl K; Hutzel S; Schmidt S; Gansser D; Ishiguro N; Taub ME; Sharma A; Ebner T; Müller F
    Br J Clin Pharmacol; 2018 Sep; 84(9):1941-1949. PubMed ID: 29665130
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug-Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects.
    Asaumi R; Toshimoto K; Tobe Y; Hashizume K; Nunoya KI; Imawaka H; Lee W; Sugiyama Y
    CPT Pharmacometrics Syst Pharmacol; 2018 Mar; 7(3):186-196. PubMed ID: 29368402
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Robust physiologically based pharmacokinetic model of rifampicin for predicting drug-drug interactions via P-glycoprotein induction and inhibition in the intestine, liver, and kidney.
    Asaumi R; Nunoya KI; Yamaura Y; Taskar KS; Sugiyama Y
    CPT Pharmacometrics Syst Pharmacol; 2022 Jul; 11(7):919-933. PubMed ID: 35570332
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of gemfibrozil, rifampicin, or probenecid on the pharmacokinetics of the SGLT2 inhibitor empagliflozin in healthy volunteers.
    Macha S; Koenen R; Sennewald R; Schöne K; Hummel N; Riedmaier S; Woerle HJ; Salsali A; Broedl UC
    Clin Ther; 2014 Feb; 36(2):280-90.e1. PubMed ID: 24491572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.